Apl clinical trials

Explore recruiting apl clinical trials.

Recruiting apl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Apl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ICC APL STUDY 02 Treatment study for children and adolescents with Acute Promyelocytic Leukemia

Netherlands, Italy, Sweden, Czechia, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met Exon14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

France, Italy, Spain, Hungary

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Spain, Netherlands, Italy, Czechia, France, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II Open-Label Pilot Trial Assessing the Safety of Anifrolumab in Adult Patients with Primary Antiphospholipid Syndrome (APS). The AnifAPS trial.

Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

Open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia

Italy, Germany, Belgium, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients with Partial Lipodystrophy

Italy, Germany, France

Therapeutic use (Phase IV) EU CTIS Study details

Apl trials by city

Apl in Toronto Apl in Vancouver Apl in Montreal Apl in Calgary Apl in Edmonton Apl in Ottawa Apl in Winnipeg Apl in Quebec City Apl in Hamilton Apl in Kitchener Apl in London Apl in Halifax Apl in New York Apl in Los Angeles Apl in Chicago Apl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease